⌕
HUTCHMED (China) · HCM · Nasdaq
Tenet 61 · Solid
Compare
$14.73−1.14%At closeTenet 61 · Solid
$14.73−0.17 (−1.14%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

HUTCHMED (China) (HCM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 15, 2026 · 23:00 ETCOMPANY'S OWN WORDS
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China Nation…

● Seeking AlphaNov 12, 2026 · 11:58 ET
HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript

HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript…

● GlobeNewsWireNov 10, 2026 · 16:03 ET
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Pha…

● PRNewsWireNov 5, 2026 · 08:00 ET
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-cont…

● GlobeNewsWireNov 4, 2026 · 19:00 ETCOMPANY'S OWN WORDS
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —…

● GlobeNewsWireNov 1, 2026 · 19:00 ETCOMPANY'S OWN WORDS
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —…

● GlobeNewsWireOct 30, 2026 · 07:30 ET
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other ser…

● GlobeNewsWireOct 28, 2026 · 20:00 ETCOMPANY'S OWN WORDS
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —  — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoi…

● GlobeNewsWireOct 26, 2026 · 20:00 ET
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces an expert webcast, co-hosted with Citigroup Global Market…

● GuruFocusOct 26, 2026 · 20:00 ET
Firms in Asia Pacific Embrace Unified Workday Platforms

Organizations across Asia Pacific are replacing fragmented legacy finance and human capital management (HCM) environments with a connected Workday platform that…

● GlobeNewsWireOct 26, 2026 · 04:30 ETCOMPANY'S OWN WORDS
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —…

● GlobeNewsWireOct 25, 2026 · 20:00 ETCOMPANY'S OWN WORDS
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine

— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® —…

● GlobeNewsWireOct 23, 2026 · 08:30 ET
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –…

● GlobeNewsWireOct 20, 2026 · 20:00 ET
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September…

● Seeking AlphaOct 20, 2026 · 08:55 ET
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product

Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting operations into 2029 …

● Defense WorldOct 16, 2026 · 02:59 ET
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) has received an average rating of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports. One analyst has rate…

● Seeking AlphaSep 30, 2026 · 14:38 ET
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More

Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1 safety data. Top-line resu…

● ReutersSep 28, 2026 · 20:18 ET
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

HUTCHMED (China) said on ​Tuesday Anglo-Swedish ‌drugmaker AstraZeneca had filed ​an ​application with the US ⁠Food ​and Drug ​Administration for approval of the ​ORPATHYS-TAGRISSO combination ​in patients with ‌advanced…

● GlobeNewsWireSep 28, 2026 · 20:00 ET
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —…

● GlobeNewsWireSep 27, 2026 · 20:00 ET
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part o…

● GlobeNewsWireSep 23, 2026 · 20:00 ET
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compou…

● MarketBeatSep 20, 2026 · 13:02 ET
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just HCM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.